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2Abstract
Introduction
There is a growing number of clinical trials in patients with head and neck cancer. Although
not often the primary outcome, patient reported outcomes (PROs) are now an important
component. The aim of this structured review was to identify and report the characteristics of
the questionnaires used in clinical trials and summarise the findings in the literature.
Materials and methods
A search of several online databases was devised using the following key terms: head and
neck oncology, head and neck surgery, reconstruction, clinical trials patient-reported
outcomes, questionnaires, Quality of Life (QoL), validated instruments, and patient
satisfaction. Information was collected relating to the topic of the paper, sample size,
selection criteria, the main advantages and disadvantages of the PRO used, and if the tool was
used in conjunction with any other.
Results
1342 papers were screened, of which 54 articles eligible; across these papers, 22
questionnaires were identified. The primary reason for utilising a tool was its relevance to the
focus of the paper such as xerostomia, pain or swallowing.
Discussion
We recommend that outcome measures for clinical trials should be chosen in relation to the
following criteria: appropriateness, reliability, validity, responsiveness, precision,
interpretability, acceptability and feasibility; to allow the patient experience to be the focus of
the primary outcome. Clinical trials use validated questionnaires but the PRO measures
3tended not to be the focus of the trial. There is merit in future clinical trials having PRO
measures as the primary outcome and designed around an explicit hypothesis.
4Introduction
Measurement of patient QoL is imperative as UK head and neck cancer incidence is
increasing.
1
The associated debilitating physiological and psychological morbidities may thus
become more prevalent
2
. Side effects of treatment and functional difficulties can exacerbate
emotional distress, depression, and self-esteem issues. The scope of randomised controlled
trials in head and neck cancer is treatment; many compare toxicity of different treatment
regimens or provide ideal interventions for side effects such as xerostomia. However, there is
no universal instrument that is sufficiently robust to compare QoL and morbidity in patients
followed up after initial surgical resection, chemotherapy and radiotherapy
3
.
Clinicians find it difficult to determine precisely what physical and emotional trauma affects
each patient after initial head and neck cancer management, and to what severity. However, it
is these very effects that affect adherence, compliance, morbidity and mortality
4
. It is here
that patient-related outcomes become paramount. This review aims to summarise the
literature in respect to the PROM used, the focus of the research and the key clinical findings.
Materials and methods
A search strategy was devised using the following key terms: head and neck oncology, head
and neck surgery, reconstruction, clinical trials, patient-reported outcomes, questionnaires,
QoL, validated instruments, and patient satisfaction. The following databases were examined:
Handle-on-qol, Medline, Ebase (Excerpta Medica), HAPI (Health and Psychosocial
Instruments), Science Citation Index/Social Sciences Citation Index, Ovid Evidence-Based
Medicine databases and PsychINFO.
5Only manuscripts written in English were included. All instruments included in the review
were identified as PROMs measuring head and neck-related QoL and/or satisfaction that had
undergone development and validation with head and neck cancer patients. PRISMA
guidance was considered in the search and presentation of the results
5
. A total of 2072 papers
were identified describing QoL (QOL) measures. From an evaluation of the abstracts and
available full text, 54
6-59
relevant papers were closely examined (Figure 1). For the appraisal
of the psychometric and operational performance of the instruments we looked for evidence
of criteria as in Table 1
60
.
Results
From 54 papers
6-59
, the authors found 22 instruments, which satisfied our inclusion criteria
(Figure 1). In many studies, the authors used more than one instrument. The most common
tool used in the search was the EORTC QLQ C30, with its use in 18 of the 54 papers. The
second most common was the EORTC QLQ-H&N35 tool which was used in 14 papers. The
above two instruments are intended to be utilised together, which was the case in 11 papers.
The primary reason for utilisation of a tool was for its ability to be general or specific when
measuring QoL (Table 2). Papers favoured tools that were well-validated, easy to use, and
those that had a focus on functional and psychological aspects of QoL. Conversely,
disadvantages were deemed to be a lack of relevance to the focus of the paper, low levels of
completion, and those that required large numbers for statistical significance. Table 3
summarises the main foci of the clinical trials.
6Discussion
In the included papers, PROMs are generally utilised as a secondary outcome to quantify the
effect of a treatment modality, rather than as a primary outcome in relation to the patient
experience. In undertaking this review, the authors are aware of its limitations: by including
papers only written in English, there is exclusion of a potentially large number of studies that
could give further insight into how PROMs are utilised. In addition, there were restrictions in
obtaining further papers by an inability to access the full text in our searches. The authors
recommend that outcome measures for clinical trials should be chosen in relation to the
criteria stated in Table 1. Analysis of the papers allows us to determine the key focus of the
trial and why each PRO instrument was utilised.
General Instruments
EQ-5D assesses mobility, self-care, usual activities, pain and anxiety. The instrument was
developed for clinical and economic evaluation of healthcare and was designed for use
alongside condition-specific instruments
59
. The instrument was used by one study
19
, assessing
PET-CT surveillance versus neck dissection in advanced head and neck cancer. EQ-5D was
used along with EORTC QLQ-C30, H&N35 and MD Anderson Dysphagia Index (Table 4).
Mehanna et al
19
commented on the utilisation of EQ-5D in deriving quality adjusted life years
to assess economic viability between the treatment groups.
COOP-WONCA Functional status charts assess general functional status aimed at primary
care; the domains include: physical fitness, feelings, daily activities, social activities, change
in health and overall health. COOP-WONCA charts were used by Van Bokhorst et al
22
in
their trial assessing perioperative enteral nutrition and QoL of severely malnourished patients.
The COOP-WONCA charts are not specific for cancer and so were used along with EORTC
7QLQ-C30. Van Bokhorst concluded that the COOP-WONCA charts were not sensitive
enough to pick up significant changes in QoL
22
.
Cancer-specific Instruments
EORTC QLQ C30 consists of a general QoL questionnaire composed of functional scales,
symptom scales, a global health status and QoL status. The questionnaire was acceptable to
patients with 60% completing it in less than 30 minutes
61
. Eighteen randomised control trials
used the EORTC QLQ C30, more than any other measure (Table 4). Eleven studies used
EORTC QLQ C30 with the QLQ-H&N35 as is intended. The focus of most papers which
utilised EORTC QLQ C30 was different chemotherapy medications and their effectiveness.
The Spitzer QoL index
62
covers 5 domains: activity, daily living, health, support and outlook.
The instrument was used by two studies in the review, Robert et al
49
were assessing a novel
chemotherapy regime and Elliot et al
50
were measuring the effectiveness of a medication in
preventing radiation mucositis. It was commented that if one question in the index is not
answered the results cannot be interpreted which could be an issue in smaller studies; in
addition, the index may be subject to patient and reviewer bias
50
.
The Rotterdam Symptom checklist (RSCL)
63
consists of four main scales: physical symptom
distress, psychological distress, activity level, and overall valuation of life. Griffiths et al
51
were the only trial to use this instrument. The paper assessed QoL in patients on the
continuous hyper-fractionated accelerated radiotherapy randomised trial, which showed there
was no clear difference in QoL compared to conventional radiotherapy. The authors modified
the checklist by adding four domains: cough, coughing up blood, hoarseness and restlessness.
Griffiths
51
used the RSCL alongside the Hospital Anxiety and Depression Scale.
8Head and Neck Cancer-specific Instruments
The EORTC Head and Neck cancer module (QLQ-H&N35) is a module which is designed to
be used in conjunction with the EORTC QLQ C30
64
. This consists of scales including pain,
swallowing, senses, speech, social eating, social contact and sexuality. 11 papers used the
EORTC QLQ C30 in conjunction with QLQ-H&N35, 7 used EORTC QLQ C30 without the
Head and neck module and 3 used the QLQ-H&N35 without the EORTC QLQ C30 (Table
4). The focus the papers was in the comparison of different treatment regimes, particularly
chemotherapeutic agents which was the case for 7 of the 11 papers.
The QoL Radiation Therapy Instrument (QoL-RTI)
65
is designed specifically for radiation
therapy. The instrument was used by one study in our search which was assessing the effect
of a novel radiotherapy regime. The regime showed QoL returned to baseline after 1 month
of treatment and it had acceptable toxicity. The instrument was acceptable to patients with
90% completing both pre-treatment and end of treatment questionnaires, but compliance
reduced between month 3 and month 12 post treatment
58
.
The University of Washington QoL questionnaire is a head and neck-specific instrument
66
. 9
papers used the UoWQoL (Table 4), two of which used it in conjunction with the Neck
Dissection Impairment Index
67
and the University of Michigan Xerostomia Questionnaire
68
.
The purpose of most the papers was to assess the effectiveness of different radioprotective
regimes during radiotherapy; however, most papers saw that there was still a decrease in QoL
despite intervention. The authors of these papers praised the UoWQoL as a general health
measure but commented that it was insensitive to changes regarding xerostomia. Owen et al
34
found a lack of compliance to completion.
9The ROTG modified University of Washington Head and Neck Symptom Questionnaire is
essentially the same as the UoWQoL but focuses more on the effects of radiation in the head
and neck
38
. It is used by three studies assessing the symptoms of patients undergoing
radiotherapy who found that there is a negative change in QoL scores following treatment,
particularly in relation to mucositis and xerostomia
38,39,40
(Table 4).
The University of Michigan Xerostomia-related QoL scale
68
is specific to mouth and throat
dryness. Four of the papers included used this instrument, all of which measured QoL in
different radiotherapy techniques; those with parotid-sparing had an increase in QoL
compared to other regimes (Table 4).
The Neck Dissection impairment index (NDII)
69
is designed to assess function, particularly
related to the shoulder, following neck dissection. This instrument was used in two studies to
assess the effects of different treatments, including exercises and TENS, on QoL. There was
found to be no statistical significance between treatments in either study. Both studies used
the index along with more general head and neck indices for an overall view of QoL. The
NDII was praised for its simplicity and specificity to neck dissection related QoL (Table 4).
The Performance Status Scale for Head and Neck Cancer
70
is a clinician-rated instrument.
The three domains are understandable speech, normalcy of diet and eating in public. Three
separate studies used the PSS-HN, one in conjunction with H&N35 and EORTC QLQ-C30
and one in conjunction with the MD Anderson Dysphagia inventory (Table 4). The studies
showed that chemoradiotherapy causes a deterioration in QoL but that there is no difference
between different chemoradiotherapy regimes.
10
Functional Assessment of Cancer Therapy-Head and Neck
71
is a self-reported instrument; the
domains are physical, social, emotional, and functional well-being. Five studies in this review
used FACT-HN, reporting it useful for functional assessment; the papers evaluated the
difference in efficacy and QoL between different chemoradiotherapy regimes. There was
found to be no difference in QoL between treatment and control groups in all the studies.
Simon et al
38
reported low completion rates (60%) in their study comparing Gefitinib with
methotrexate. Most studies reported the FACT-HN’s utility in measuring functional
performance for patients with head and neck cancer. (Table 4)
The FHNSI-10 is aimed at patients with refractory, recurrent or advanced disease. It is a
subset of the FACT H&N
71
and was designed to capture physical symptoms of disease. Two
studies used the FHNSI-10; Stewart et al
43
utilised it in conjunction with the Functional
Assessment of Cancer Therapy H&N instrument, as they reported that FHNSI-10 is
ineffective for assessing general QoL. Again, the studies were assessing different
chemotherapy regimens; no mention was made of patient acceptability
70
.
The MD Anderson Dysphagia Inventory (MDADI)
72
is a self-administered instrument for
assessing dysphagia; it includes items grouped into domains of dysphagia; global, emotional,
functional and physical. The inventory was used by two studies in our review both of which
praised it for its specific use with swallowing, but also used a more general measure
alongside (Table 4). Hutcheson et al
45
used the study to assess QoL following
chemoradiotherapy which was found to decrease.
11
The Head and Neck Radiotherapy Questionnaire
73
is directed towards physical symptoms of
skin, throat, stomatitis, digestion, energy and psychosocial for head and neck radiotherapy
patients. All four of the studies that used this instrument were related to the prevention of
xerostomia in patients undergoing radiotherapy; most radioprotective agents did not have a
significant effect on QoL. Ringash et al complimented the disease specificity and ease of
completion, however they also comment that data from healthy individuals is not available
and while the score can remain the same the patients may have swapped pre-treatment
problems with post-treatment problems
74
.
The Head and Neck cancer specific -QoL (HNQoL)
75
is a validated QoL instrument divided
into four domains: eating and swallowing, communication, head and neck pain and emotional
wellbeing. The only study to utilise this instrument identified QoL between patients who
underwent chemoradiotherapy plus a neck dissection versus chemotherapy alone; no
difference in QoL was found. Donatelli-Lassig et al
59
determined that the disease specificity
of the HNQoL was a useful feature.
Head and Neck Cancer inventory (HNCI) is a reliable validated health status instrument.
Lazarus et al
55
utilised this study in assessing swallowing and tongue strength exercises in
patients who underwent primary chemotherapy with or without adjuvant chemotherapy.
Those who underwent exercises had an increase in QoL.
Miscellaneous Instruments
The Hospital Anxiety and Depression Scale
76
is an instrument with two domains (anxiety and
depression). Four studies in the sample used the HADS which focussed on whether
implantation of coping strategies improved QoL, which was found to be the case. All the
12
studies commented that it was a useful psychological test, but Scheifke et al
9
commented the
need to use another instrument for a more rounded assessment.
The Dermatology life quality index is a dermatology-specific QoL instrument
77
. It was
utilised by one trial in the search which was based on skin symptoms associated with
etuximab. The trial also used the EORTC QLQ-C30 (Table 4).
The Hearing Handicap Inventory for the Elderly is a specific instrument for assessing QoL
issues due to hearing loss. The instrument is valid, reliable and easy to use
78
. Schultz et al
57
were the only study to use this instrument, utilising it for hearing loss associated with head
and neck cancer, showing that patients undergoing radiotherapy are more likely to have
hearing related problems.
The Modified WHO performance status scale is a five-point scale based on ability to work
and is not a true QoL instrument
79
; it was utilised by Correy et al
56
in the assessment of PEG
vs NG tubes, where there was found to be no significant different in QoL.
Conclusion
There have been a variety of questionnaires used in clinical trials following H&N cancer;
these have tended to be secondary outcomes. It is important when focusing on patient
reported outcomes to include a validated questionnaire that is optimal to the hypothesis being
tested between arms of the trial. It is worthwhile considering more than one questionnaire and
to be as specific as possible in selection; in addition, anchoring a PROM with an objective
measurement will be beneficial in ensuring the patient experience as the primary outcome.
Although underlying issues have been widely discussed, three of our criteria:
13
appropriateness, precision and interpretability, are not always included in lists of desirable
properties of instruments. The remaining five criteria are widely cited and identified in the
same or similar terminology as in this review (Table 1).
The choice of questionnaire in clinical trials is largely depended on the hypothesis being
tested. From this structure review, it is evident that we could not recommend the use of a
specific instrument. In clinical trials in head and neck cancer –investigating the impact of
different treatments-the EORTC -C30 with the H&N-35 module has been used more
frequently as a secondary outcome. The lack of discrimination of general questionnaires may
be a reason why researchers favoured established tools such as the EORTC. In addition, the
majority of the clinical trials that included HRQOL instruments involved adjuvant treatments
with marginal differences in outcomes.
In this review, the main areas where PROs were used in clinical trials were for evaluating the
differences between different chemotherapy medications, the differences in techniques for
preventing xerostomia, and between different radiotherapy regimes, amongst others. For the
main, there was little difference in QoL between different treatment regimens; those papers
that focussed on specific patient experience measures such as implementation of coping
strategies, found an increase in QoL. In the future, trials can be broadened to include PROs as
the primary outcome with an explicit hypothesis.
Conflict of interest: The authors have no conflict of interest to declare.
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Validity
Reliability
Responsiveness
Appropriateness
Precision
Interpretability
Acceptability
Feasibility
Table 1. Criteria required to be evidenced by the instruments
25
Type of PRO
instrument
Number of
instruments
Names of instruments
General 2 EQ-5D
59
; COOP-WONCA
22
Cancer Specific 3 EORTC QLQ C30
61
; Spitzer QoL
62
; Rotterdam Symptom
Checklist
63
Head & Neck
Cancer Specific
13 EORTC QLQ-H&N35
64
; University of Washington
QoL
66
; ROTG Modified University of Washington QoL
38
;
University of Michigan Xerostomia Questionnaire
68
; QoL-
RTI
65
; NDII
67
; PSS H&N
70
; MD Anderson Dysphagia
Inventory
72
; FACT H&N
71
, FHNSI-10
70
; H&N QoL
75
;
HNCI
55
; H&N Radiotherapy Questionnaire
73
Miscellaneous 4 Hospital Anxiety & Depression Scale
76
; Hearing Handicap
Inventory
78
; Dermatology Life Questionnaire
77
; Modified
WHO PS
79
Table 2. Types of Patient Reported Outcome (PRO) instrument used
26
Focus of the Trial Number of Trials with this Focus
Chemotherapy/ Chemoradiotherapy regimes 13
Xerostomia/ Mucositis 12
Radiotherapy regimes 11
Dietary intake 3
Psychosocial interventions 2
Pain medications 2
QoL 2
Coping strategies 2
PET CT vs SND for monitoring 1
Hyperbaric oxygen therapy 1
Utilising EMG studies 1
Shoulder exercises 1
Dermatitis 1
Hearing Loss 1
Swallowing 1
Table 3. Focus of clinical trials
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Figure 1 Search results included in the review
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Questionnaire First Author/ Year Focus of the RCT Number of
patients
Inclusion & Exclusion
Criteria
Main Advantages Main Disadvantages Other Instruments
EORTC QLQ-
C30
Duncan et al 2005
6
Xerostomia/Mucositis 138 Non-metastatic; had RT Broad view of QoL
Brief
Validated
Not specific to oral cavity as
needed
Not H&N specific
Rivera et al 2009
7
Chemotherapy in
metastatic disease
442 Recurrent or metastatic
cancer
Cancer-specific
Self-administered
Multi-dimensional
HN35
Machiels et al 2015
8
Chemotherapy in
metastatic disease
483 Recurrent or metastatic
cancer
Cancer-specific
Validated
HN35
Potthoff et al 2014
9
Medication for pain
intensity
34 Cetuximab
chemoradiotherapy
rhagades
Cancer-specific
Broad view of heath
Pt recorded
Dermatological Life
Quality Index
Bottomley et al
2013
10
Chemotherapy vs
chemoradiotherapy
450 Neck nodes but no
metastases
Broad view of health H&N35
Van Herpen et al
2010
11
Symptom control 358 Unresectable, advanced
SCC
Robust
Validated
Frequently used in RCTs
Functional & symptomatic
scales
Not H&N specific H&N35
Machiels et al 2014
12
Chemotherapy in
metastatic disease
474 Recurrent SCC not
amenable to salvage
Good scale for measuring
pain
H&N35
Mesia et al 2010
13
Chemotherapy medication 442 Previously untreated
advanced SCC
Cancer-specific
Broad view of heath
Lack of compliance to
completion
H&N35
Schiefke et al 2008
14
QoL after SND 49 Sentinel node bx or SND Validated
Reliable
May need large numbers for
statistical significance
H&N35
Hospital Anxiety and
Depression Scale
Ackerstaff et al Chemotherapy medication 207 Ineligible for salvage Validated H&N35
29
2008
15
surgery
Vilela et al 2005
16
Coping strategy therapy 101 Completed cancer
treatment
Validated Hospital Anxiety and
Depression Scale
Heukelom et al
2013
17
Chemoradiotherapy 268 T3/4 tumour new
diagnosis
Validated H&N35
Uster et al 2013
18
Dietary intake post H&N
cancer
58 Those who would benefit
from nutritional support
Cancer-specific Not specific to nutrition
Mehanna et al 2016
19
PET-CT in advanced SCC 564 N2 or N3 metastases Validated
Frequently used
Not H&N specific EQ-5D
Hi 35
MD Anderson dysphagia
Teguh et al 2009
20
Hyperbaric oxygen 19 RT treatment tongue SCC Validated Performance Status Scale for
Head and Neck Cancer
H&N35
Fang et al 2008
21
Different RT rxs 203 Requiring radical RT Validated H&N35
Van bokhorst et al
2000
22
Enteral nutrition 49 Malnourished Cancer-specific
Validated
COOP-WONCA
Myers et al 1999
23
Psychosocial intervention 47 H&N SCC, no previous
mental health issue
Cancer-specific Hospital Anxiety and
Depression Scale
EORTC QLQ-
H&N35
Rivera et al 2009
7
Chemotherapy in
metastatic disease
442 Recurrent or metastatic
cancer
H&N cancer-specific Low completion
May not be relevant for
general QoL factors
EORTC QLQ-C30
Machiels et al 2015
8
Chemotherapy in
metastatic disease
483 Recurrent or metastatic
cancer
Validated EORTC QLQ-C30
Bottomley et al
2013
10
Chemotherapy vs
chemoradiotherapy
450 Neck nodes but no
metastases
Designed for surgery,
radiotherapy and
chemoradiotherapy
EORTC QLQ-C30
Van Herpen et al
2010
11
Symptom control 358 Unresectable, advanced
SCC
Specific to H&N i.e.
xerostomia etc, Good
previous use in caner clinical
trials
EORTC QLQ-C30
30
Machiels et al 2014
12
Chemotherapy in
metastatic disease
474 Recurrent SCC not
amenable to salvage
H&N specific EORTC QLQ-C30
Mesia et al 2010
13
Chemotherapy medication 442 Previously untreated
advanced SCC
H&N specific EORTC QLQ-C30
Van Rij et al 2008
24
Xerostomia related to RT 192 For curative RT Good for xerostomia
Bower et al 2009
25
Effects of treatment
modalities for H&N
231 Any form of curative Rx Validated
H&N specific
Schiefke et al 2008
14
QoL after SND 49 Sentinel node bx or SND Validated
Reliable
H&N specific
May need large numbers for
statistical significance
EORTC QLQ-C30
Hospital Anxiety and
Depression Scale
Ackerstaff et al
2008
15
Chemotherapy
medications
207 Ineligible for salvage
surgery
Validated EORTC QLQ-C30
Heukelom et al
2013
17
Chemoradiotherapy 268 T3/4 tumour new
diagnosis
Validated EORTC QLQ-C30
Mehanna et al 2016
19
PET-CT in advanced SCC 564 N2 or N3 metastases H&N specific MD Anderson
Dysphagia Inventory
Teguh et al 2009
20
Hyperbaric oxygen 19 RT treatment tongue SCC H&N specific i.e swallowing Performance Status Scale for
Head and Neck Cancer
EORTC QLQ-C30
Fang et al 2008
21
Different RT regimes 203 Requiring radical RT Validated
H&N specific
EORTC QLQ-C30
University of
Michigan
Xerostomia
Questionnaire
Chang et al 2009
26
Xerostomia 15 Disease free 1yr post-
surgery; had RT
Simple
Validated
Not suitable for less invasive
RT treatments w/ lower doses
Scrimger et al 2007
27
Saliva Production 188 Bilateral RT to parotids Specific to clinical question UoWQoL
Warde et al 2000
28
Xerostomia 28 RT; no anticholinergic
medications
Simple
31
Lin et al 2003
29
Xerostomia 36 Post-parotid sparing RT H&N specific
Validated
Specific to xerostomia
May not be as useful when
sample size small
University of
Washington QoL
Scrimger et al 2007
27
Saliva Production 188 Bilateral RT to parotids Well-rounded general health
view
Insensitivity when related to
question of xerostomia
University of Michigan
Xerostomia Questionnaire
Parikh et al 2011
30
Electromyographic
studies
38 Selective neck dissection Good for functional
measures
Neck Dissection
Impairment Index
Lydiatt et al 2008
31
Depression medication 23 No pre-existing mental
health condition
Self-administered
Focuses on aspects of daily
life
Brennan et al 2009
32
Staged vs elective neck
treatment
25 T1-2 N0 SCC new
diagnosis
General health view
Oton-Leite et al
2011
33
Laser therapy with RT 60 Undergoing RT salivary
glands
Simple
Brief
Validated
Easy to complete and
interpret
H&N cancer-specific
Owen et al 2011
34
Radio frequency ablation 21 Unresectable SCC or
previously failed Rx
H&N specific Lack of compliance to
completion
Jha et al 2000
35
RT induced xerostomia 16 Eligible for RT General health view Not specific to xerostomia or
RT
Johnson et al 2002
36
Radioprotection of
mucosa
33 Resection + RT Good for functional
measures
heavily weighted on patient
symptoms
Jha et al 2003
37
Xerostomia 76 Requiring RT Good for functional
measures
RTOG-modified
University of
Washington QoL
H&N Symptom
Hoffman et al 2014
38
GM-CSF effect of RT
symptoms
114 No previous
chemoradiotherapy
Self-administered
Validated
Specific to RT
Lack of compliance to
completion
32
Heron et al 2009
39
Stereotactic body
radiotherapy
25 Recurrent SCC General health but with
specific RT aspect
Fisher et al 2003
40
Xerostomia post RT 249 RT Function specific
Good for RT
Neck Dissection
Impairment
Index
Parikh et al 2011
30
Electromyographic
studies
38 Selective neck dissection Simple University of Washington
QoL
McNeely et al 2008
41
Exercise for shoulder pain 52 Neck dissection, shoulder
dysfunction
Specific for neck dissection
issues
Functional Assessment
of Cancer Therapy
H&N
FHNSI-10 Kushwaha et al
2015
42
Palliative chemotherapy
medications
117 Pt ineligible for salvage
surgery/RT/chemo
Specific for
advanced/recurrent cancer
Brevity
Stewart et al 2009
43
Methotrexate recurrent
SCC
486 Recurrent SCC with RT
not amenable to salvage
Good for symptomatic
measures
Not useful for general health Functional Assessment of
Cancer Therapy H&N
Performance
Status Scale for
Head and Neck
Cancer
Mittal et al 2015
44
Swallowing/ Saliva
Production
13 Chemoradiotherapy H&N cancer-specific
Hutcheson et al
2014
45
Chemotherapy in relation
to swallowing
47 Untreated stage IV SCC Disease specific, Involves
another person i.e. the
clinician
Involves another person i.e.
the clinician
MD Anderson
Dysphagia Inventory
Teguh et al 2009
20
Hyperbaric oxygen 19 RT treatment tongue SCC Good for functional
activities such as swallowing
H&N35
EORTC QLQ-C30
Functional
Assessment of
Cancer Therapy
H&N
Rischin et al 2010
46
Chemoradiotherapy
effectiveness
850 Previously untreated
advanced SCC
H&N cancer-specific
Good for
chemo/radiotherapy Rx
options
Simon et al 2009
43
Methotrexate recurrent
SCC
486 Recurrent SCC with RT
not amenable to salvage
H&N cancer-specific Low completion FHNSI-10
33
Cohen et al 2006
47
Chemoradiotherapy 53 Stage II or III SCC Good focus on chemo and
radiotherapy options
McNeely et al 2008
41
Exercise for shoulder pain 52 Neck dissection, shoulder
dysfunction
Good for function &
exercise
Neck Dissection
Impairment Index
Ringash et al 2008
48
RT 171 Locally advanced SCC
III/IV
Good for function
Good for RT
MD Anderson
Dysphagia
Inventory
Hutcheson et al
2014
45
Chemotherapy in relation
to swallowing
47 Untreated stage IV SCC Specific to swallowing Needs to be used in
conjunction with another
questionnaire for more
rounded assessment
Performance Status Scale for
Head and Neck Cancer
Mehanna et al 2016
19
PET-CT in advanced SCC 564 N2 or N3 metastases Another more specific
dimension related to H&N
H&N35
Spitzer QoL
Index
Robert et al 1997
49
Chemotherapy
medications
26 Recurrent or metastatic
cancer
Related to basic living tasks Not H&N cancer specific
Elliot et al 2006
50
Prevention of radiation
dermatitis
547 Stage III or IV SCC
requiring RT
Validated
Self-assessment
May be subject to reviewer or
pt bias
Head and Neck
Radiotherapy Questionnaire
Hospital Anxiety
and Depression
Scale
Griffiths et al 1999
51
Physical & Psychological
symptoms
615 SCC treatment Psychologically specific Data needs to be analysed in
several ways to ensure
consistency
Rotterdam Symptom
Checklist
Schiefke et al 2008
14
QoL after SND 49 Sentinel node bx or SND Psychologically specific Needs to be used in
conjunction with another
questionnaire for more
rounded assessment
EORTC QLQ-C30
Vilela et al 2005
16
Coping strategy therapy 101 Completed cancer
treatment
Psychologically specific EORTC QLQ-C30
Myers et al 1999
23
Psychosocial intervention 47 H&N SCC, no previous
mental health issue
Psychologically specific EORTC QLQ-C30
Head and Neck
Radiotherapy
Questionnaire
Elliot et al 2006
50
Prevention of radiation
dermatitis
547 Stage III or IV SCC
requiring RT
H&N cancer-specific
RT specific
May be subject to reviewer or
pt bias
Spitzer QoL Index
34
Ringash et al 2005
52
Post-RT xerostomia 130 RT to parotids Validated
Cancer-specific
RT specific
Multi-dimensional
Easy to complete
Questionnaire disease specific
Uses summary scores so may
not be adequate for
xerostomia assessment
Does not assess patient
weighting of problem
Wong et al 2003
53
TENS post RT 37 Xerostomia post radial RT Easy to complete
Warde et al 2002
54
Oral pilocarpine for RT 130 RT with inclusion of
parotids
RT specific
EQ-5D Mehanna et al 2016
19
PET-CT in advanced SCC 564 N2 or N3 metastases Good for cost effectiveness
assessment
EORTC QLQ-C30
H&N35
MD Anderson dysphagia
Head and Neck
Cancer Inventory
Lazarus et al 2013
55
Swallowing/ Tongue
strength
23 Post-op SCC resection; no
pre-existing dysphagia
Good for functional scores
Modified WHO
Performance
Status Scale
Corry et al 2008
56
PEG vs NG 33 RT and needing enteral
feeding
Specific to NG tubes
Simple
Not related to cancer
Dermatological
Life Quality
Index
Potthoff et al 2014
9
Medication for pain
intensity
34 Cetuximab
chemoradiotherapy
Specific to dermatology Not related to H&N cancer EORTC QLQ-C30
Rotterdam
Symptom
Checklist
Griffiths et al 1999
51
Physical & Psychological
symptoms
615 SCC treatment Cancer specific
General view of heath
Pt recorded
Hospital Anxiety and
Depression Scale
Hearing
Handicap
Inventory for the
Elderly
Schultz et al 2010
57
Hearing loss of H&N
cancer patients
141 Had RT Specific to hearing loss Not relevant for any other
features of H&N cancer
QoL-RTI Maguire et al 2011
58
RT therapy in advanced
SCC
30 Stage III or IV SCC
requiring RT
Radiation and RT specific
Good for swallowing
measurements
Not related to other aspects of
H&N cancer
COOP-WONCA Van bokhorst et al Enteral nutrition 49 Malnourished Generic Not specific to cancer or EORTC QLQ-C30
35
2000
12
Practical
Easy
H&N
HNQoL Donatelli-Lassig et al
2008
59
QoL post
chemoradiotherapy
65 Inclusive of SND Cancer-specific
H&N specific
Table 4. Patient Reported Outcome Measures used in papers relevant to Head & Neck Cancer.
